PMID- 23200818
OWN - NLM
STAT- MEDLINE
DCOM- 20130228
LR  - 20130108
IS  - 2210-7762 (Print)
VI  - 205
IP  - 12
DP  - 2012 Dec
TI  - Deletion(20q) as the sole abnormality in plasma cell myeloma is not associated 
      with plasma cells as identified by cIg FISH.
PG  - 644-52
LID - S2210-7762(12)00257-8 [pii]
LID - 10.1016/j.cancergen.2012.10.007 [doi]
AB  - Deletion of 20q is a common finding in myeloid disorders but it is also observed 
      in plasma cell myeloma (PCM). As a del(20q) in a patient receiving treatment for 
      myeloma may indicate therapy-related myelodysplastic syndrome (t-MDS), it is 
      important to differentiate chromosome abnormalities associated with myeloma from 
      those reflecting t-MDS. We performed fluorescence in situ hybridization (FISH) 
      using a 20q12 probe (D20S108) in conjunction with cytoplasmic immunoglobulin 
      (cIg) staining in 20 PCM cases with a del(20q) in order to confirm the cell type 
      involved. Of the nine cases studied with a clone showing a del(20q) as the sole 
      abnormality, 8 of 9 demonstrated loss of the D20S108 signals in non-plasma cells 
      only and 5 of 9 had either a confirmed myeloid malignancy in addition to PCM or 
      showed evidence of dysplastic changes in the marrow; however, of the 11 patients 
      with a del(20q) within a complex PCM karyotype, 4 of 11 showed loss of the 
      D20S108 signals in plasma cells only and 7 of 11 showed no significant loss in 
      either plasma cells or non-plasma cells. Therefore, our results indicate that a 
      del(20q) as the sole abnormality in PCM is present in non-plasma cells and, 
      therefore, suggests the presence of an associated myeloid malignancy.
CI  - Copyright (c) 2012 Elsevier Inc. All rights reserved.
FAU - White, Joanne S
AU  - White JS
AD  - Victorian Cancer Cytogenetics Service, St. Vincent's Hospital Melbourne, Fitzroy, 
      Australia. jo.white@svhm.org.au
FAU - Zordan, Adrian
AU  - Zordan A
FAU - Batzios, Crisoula
AU  - Batzios C
FAU - Campbell, Lynda J
AU  - Campbell LJ
LA  - eng
PT  - Journal Article
DEP - 20121130
PL  - United States
TA  - Cancer Genet
JT  - Cancer genetics
JID - 101539150
RN  - 0 (DNA Probes)
RN  - 0 (Immunoglobulins)
SB  - IM
MH  - Aged
MH  - Aged, 80 and over
MH  - Cell Nucleus/metabolism
MH  - *Chromosome Deletion
MH  - Chromosomes, Human, Pair 20/*genetics
MH  - Cytoplasm/metabolism
MH  - DNA Probes/metabolism
MH  - Female
MH  - Humans
MH  - Immunoglobulins/*metabolism
MH  - In Situ Hybridization, Fluorescence/*methods
MH  - Male
MH  - Middle Aged
MH  - Multiple Myeloma/*genetics/*pathology
MH  - Plasma Cells/*pathology
EDAT- 2012/12/04 06:00
MHDA- 2013/03/01 06:00
CRDT- 2012/12/04 06:00
PHST- 2012/05/24 00:00 [received]
PHST- 2012/10/09 00:00 [revised]
PHST- 2012/10/12 00:00 [accepted]
PHST- 2012/12/04 06:00 [entrez]
PHST- 2012/12/04 06:00 [pubmed]
PHST- 2013/03/01 06:00 [medline]
AID - S2210-7762(12)00257-8 [pii]
AID - 10.1016/j.cancergen.2012.10.007 [doi]
PST - ppublish
SO  - Cancer Genet. 2012 Dec;205(12):644-52. doi: 10.1016/j.cancergen.2012.10.007. Epub 
      2012 Nov 30.